
## Claus F Vogelmeier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7084336/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clinical Research in Cardiology, 2023, 112, 177-186.	3.3	9
2	Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function. European Radiology, 2022, 32, 1879-1890.	4.5	18
3	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	5.6	72
4	Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 631-640.	5.6	18
5	lgE is associated with exacerbations and lung function decline in COPD. Respiratory Research, 2022, 23, 1.	3.6	21
6	A scoping review of mHealth monitoring of pediatric bronchial asthma before and during COVID-19 pandemic. Paediatric Respiratory Reviews, 2022, 43, 67-77.	1.8	5
7	Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. Scientific Reports, 2022, 12, 1435.	3.3	8
8	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. Respiration, 2022, 101, 307-320.	2.6	5
9	Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. International Journal of COPD, 2022, Volume 17, 355-370.	2.3	5
10	Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD â€real world' study. Respiratory Research, 2022, 23, 109.	3.6	4
11	Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine, 2022, , 106918.	2.9	0
12	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 17-24.	5.6	57
13	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy, 2022, 39, 3957-3978.	2.9	10
14	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 24-36.	5.6	417
15	Deterioration and Mortality Risk of COPD Patients Not Fitting into Standard GOLD Categories: Results of the COSYCONET Cohort. Respiration, 2021, 100, 308-317.	2.6	5
16	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
17	COPD & amp; COVID-19. Archivos De Bronconeumologia, 2021, 57, 162-164.	0.8	6
18	COPD & amp; COVID-19. Archivos De Bronconeumologia, 2021, 57, 162-164.	0.8	11

2

#	Article	IF	CITATIONS
19	Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Research, 2021, 7, 00108-2021.	2.6	133
20	Burden of Pertussis in COPD: A Retrospective Database Study in England. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 157-169.	1.6	21
21	Constitutive immune activity promotes JNK- and FoxO-dependent remodeling of Drosophila airways. Cell Reports, 2021, 35, 108956.	6.4	22
22	Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany. Respiratory Research, 2021, 22, 108.	3.6	22
23	Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences. International Journal of COPD, 2021, Volume 16, 987-998.	2.3	9
24	Transcriptional analysis identifies potential biomarkers and molecular regulators in acute malaria infection. Life Sciences, 2021, 270, 119158.	4.3	5
25	Echo <scp>Timeâ€Dependent</scp> Observed Lung <scp>T<sub>1</sub></scp> in Patients With Chronic Obstructive Pulmonary Disease in Correlation With Quantitative Imaging and Clinical Indices. Journal of Magnetic Resonance Imaging, 2021, 54, 1562-1571.	3.4	6
26	Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. International Journal of COPD, 2021, Volume 16, 1215-1226.	2.3	8
27	Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2255-2261.	3.8	76
28	Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-NaÃ⁻ve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of COPD, 2021, Volume 16, 1939-1956.	2.3	6
29	Pulmonary rehabilitation in long COVID: more than just natural recovery!?. ERJ Open Research, 2021, 7, 00454-2021.	2.6	14
30	Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease. Kidney International, 2021, 100, 1081-1091.	5.2	10
31	Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET. ERJ Open Research, 2021, 7, 00242-2021.	2.6	8
32	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy, 2021, 38, 4815-4835.	2.9	4
33	COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. Respiratory Medicine, 2021, 185, 106461.	2.9	14
34	COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany. International Journal of COPD, 2021, Volume 16, 2407-2417.	2.3	12
35	Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data. International Journal of COPD, 2021, Volume 16, 2637-2651.	2.3	7
36	Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET. Respiratory Research, 2021, 22, 242.	3.6	7

#	Article	IF	CITATIONS
37	COVID-19 and COPD: lessons beyond the pandemic. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L978-L982.	2.9	7
38	Implementation and use of mHealth home telemonitoring in adults with acute COVID-19 infection: a scoping review protocol. BMJ Open, 2021, 11, e053819.	1.9	7
39	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	5.6	121
40	Use of the Evaluating Respiratory Symptomsâ,,¢ in COPD as an Outcome Measure in Clinical Trials: A Rapid Systematic Review. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2021, 8, 551-571.	0.7	2
41	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	6.7	8
42	Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial. Respiratory Research, 2021, 22, 279.	3.6	4
43	Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. International Journal of COPD, 2021, Volume 16, 3189-3199.	2.3	5
44	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	2.3	2
45	Time-updated resting heart rate predicts mortality in patients with COPD. Clinical Research in Cardiology, 2020, 109, 776-786.	3.3	11
46	High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. European Respiratory Journal, 2020, 55, 1901314.	6.7	26
47	Exacerbations of chronic obstructive pulmonary disease: time to rename. Lancet Respiratory Medicine,the, 2020, 8, 133-135.	10.7	13
48	Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. Respiratory Medicine, 2020, 172, 106117.	2.9	4
49	COPD 2020: changes and challenges. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L879-L883.	2.9	66
50	Assessing Symptom Burden. Clinics in Chest Medicine, 2020, 41, 367-373.	2.1	4
51	Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort. Respiratory Medicine, 2020, 171, 106087.	2.9	11
52	Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study. International Journal of COPD, 2020, Volume 15, 2739-2750.	2.3	0
53	Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Research, 2020, 6, 00092-2020.	2.6	16
54	<p>Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients</p> . International Journal of COPD, 2020, Volume 15, 1831-1838.	2.3	3

#	Article	IF	CITATIONS
55	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials. Advances in Therapy, 2020, 37, 4266-4279.	2.9	10
56	Impact of baseline COPD symptom severity on the benefit from dual <i>versus</i> mono-bronchodilators: an analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096850.	2.6	7
57	<p>Impact of Education on COPD Severity and All-Cause Mortality in Lifetime Never-Smokers and Longtime Ex-Smokers: Results of the COSYCONET Cohort</p> . International Journal of COPD, 2020, Volume 15, 2787-2798.	2.3	13
58	Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort. BMC Pulmonary Medicine, 2020, 20, 148.	2.0	15
59	COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study. Lung, 2020, 198, 507-514.	3.3	2
60	Update in Chronic Obstructive Pulmonary Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 348-355.	5.6	20
61	Early and sustained symptom improvement with umeclidinium/vilanterol <i>versus</i> monotherapy in COPD: a <i>post hoc</i> analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092694.	2.6	4
62	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
63	Goals of COPD treatment: Focus on symptoms and exacerbations. Respiratory Medicine, 2020, 166, 105938.	2.9	135
64	Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation. Scientific Reports, 2020, 10, 241.	3.3	17
65	SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries. Advances in Therapy, 2020, 37, 1124-1135.	2.9	84
66	COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respiratory Medicine, 2020, 173, 106175.	2.9	4
67	Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. Chronic Respiratory Disease, 2019, 16, 147997231877542.	2.4	11
68	Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respiratory Research, 2019, 20, 178.	3.6	34
69	Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respiratory Research, 2019, 20, 151.	3.6	33
70	<p>Personalized medicine for patients with COPD: where are we?</p> . International Journal of COPD, 2019, Volume 14, 1465-1484.	2.3	55
71	>Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. International Journal of COPD, 2019, Volume 14, 1423-1439.	2.3	24
72	lt is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 2019, 54, 1900914.	6.7	43

#	Article	IF	CITATIONS
73	<p>Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort</p> . Patient Preference and Adherence, 2019, Volume 13, 1711-1721.	1.8	10
74	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research, 2019, 20, 238.	3.6	81
75	CAT score single item analysis in patients with COPD: Results from COSYCONET. Respiratory Medicine, 2019, 159, 105810.	2.9	16
76	<p>Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort</p> . International Journal of COPD, 2019, Volume 14, 2163-2172.	2.3	35
77	Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients. Cells, 2019, 8, 1162.	4.1	26
78	Prevalence and Characteristics of Asthma–Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. Annals of the American Thoracic Society, 2019, 16, 1143-1150.	3.2	32
79	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	27.0	180
80	<p>Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population</p> . International Journal of COPD, 2019, Volume 14, 853-861.	2.3	20
81	Treatment response in COPD: does FEV <sub>1</sub> say it all? A <i>post hoc</i> analysis of the CRYSTAL study. ERJ Open Research, 2019, 5, 00243-2018.	2.6	18
82	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
83	Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. Respiratory Research, 2019, 20, 61.	3.6	11
84	Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respiratory Research, 2019, 20, 30.	3.6	26
85	Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Research, 2019, 5, 00106-2019.	2.6	21
86	The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respiratory Research, 2019, 20, 257.	3.6	13
87	Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. European Respiratory Journal, 2019, 54, 1900673.	6.7	55
88	Proviral MicroRNAs Detected in Extracellular Vesicles From Bronchoalveolar Lavage Fluid of Patients With Influenza Virus–Induced Acute Respiratory Distress Syndrome. Journal of Infectious Diseases, 2019, 219, 540-543.	4.0	40
89	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	3.2	11
90	The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study. Journal of Epidemiology, 2019, 29, 315-324.	2.4	27

#	Article	IF	CITATIONS
91	Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respiratory Medicine, 2018, 137, 14-22.	2.9	35
92	Left ventricular volume and wall stress are linked to lung function impairment in COPD. International Journal of Cardiology, 2018, 261, 172-178.	1.7	27
93	Pharmacological treatment of COPD: the devil is always in the detail. European Respiratory Journal, 2018, 51, 1800263.	6.7	16
94	Exacerbations of COPD. European Respiratory Review, 2018, 27, 170103.	7.1	189
95	The revised GOLD 2017 COPD categorization in relation to comorbidities. Respiratory Medicine, 2018, 134, 79-85.	2.9	45
96	Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respiratory Research, 2018, 19, 251.	3.6	28
97	Safety of biweekly α <sub>1</sub> -antitrypsin treatment in the RAPID programme. European Respiratory Journal, 2018, 52, 1800897.	6.7	10
98	Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA. International Journal of COPD, 2018, Volume 13, 1455-1468.	2.3	10
99	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. International Journal of COPD, 2018, Volume 13, 1125-1134.	2.3	14
100	Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics, Proteomics and Bioinformatics, 2018, 16, 162-171.	6.9	33
101	Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respiratory Research, 2018, 19, 110.	3.6	35
102	Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respiratory Research, 2018, 19, 11.	3.6	22
103	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	5.6	2,393
104	Myocardial homing of mesenchymal stem cells following intrapericardial application and amplification by inflammation — an experimental pilot study. Canadian Journal of Physiology and Pharmacology, 2017, 95, 1064-1066.	1.4	2
105	Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1189-1197.	5.6	139
106	A two-year evaluation of the â€~real life' impact of COPD on patients in Germany: The DACCORD observational study. Respiratory Medicine, 2017, 124, 57-64.	2.9	33
107	Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1219-1221.	5.6	100
108	Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. Advances in Therapy, 2017, 34, 281-299.	2.9	26

#	Article	IF	CITATIONS
109	Precision medicine in airway diseases: moving to clinical practice. European Respiratory Journal, 2017, 50, 1701655.	6.7	151
110	GOLD 2017 treatment pathways in â€~real life': An analysis of the DACCORD observational study. Respiratory Medicine, 2017, 131, 77-84.	2.9	27
111	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	6.7	64
112	European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α <sub>1</sub> -antitrypsin deficiency. European Respiratory Journal, 2017, 50, 1700610.	6.7	244
113	Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ. Respiratory Medicine, 2017, 130, 1-8.	2.9	6
114	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. European Respiratory Journal, 2017, 50, 1700671.	6.7	69
115	Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respiratory Research, 2017, 18, 14.	3.6	15
116	Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respiratory Research, 2017, 18, 60.	3.6	15
117	New concepts in asthma: clinical phenotypes and pathophysiological mechanisms. Drug Discovery Today, 2017, 22, 388-396.	6.4	39
118	Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences–Comorbidities Network Study. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 189-197.	5.6	81
119	Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine, 2017, 122, 58-66.	2.9	30
120	Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respiratory Research, 2017, 18, 171.	3.6	27
121	Perception of symptoms and quality of life – comparison of patients' and physicians' views in the COPD MIRROR study. International Journal of COPD, 2017, Volume 12, 2189-2196.	2.3	43
122	The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. International Journal of COPD, 2017, Volume 12, 1325-1337.	2.3	40
123	"Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. International Journal of COPD, 2017, Volume 12, 487-494.	2.3	47
124	Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research, 2017, 18, 140.	3.6	52
125	Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry. International Journal of COPD, 2017, Volume 12, 1427-1437.	2.3	7
126	Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS ONE, 2017, 12, e0177501.	2.5	37

#	Article	IF	CITATIONS
127	A year in the life of German patients with COPD: the DACCORD observational study. International Journal of COPD, 2016, Volume 11, 1639-1646.	2.3	28
128	Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis. International Journal of COPD, 2016, Volume 11, 3189-3197.	2.3	16
129	Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. Respiratory Research, 2016, 17, 81.	3.6	25
130	The â€~real-life' COPD patient in Germany: The DACCORD study. Respiratory Medicine, 2016, 111, 64-71.	2.9	58
131	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respiratory Medicine, 2016, 114, 27-37.	2.9	113
132	Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respiratory Medicine,the, 2016, 4, 390-398.	10.7	349
133	Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulmonary Medicine, 2016, 16, 70.	2.0	81
134	Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. New England Journal of Medicine, 2016, 374, 2222-2234.	27.0	688
135	Efficacy and safety of aclidinium/formoterol <i>versus</i> salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal, 2016, 48, 1030-1039.	6.7	81
136	A review of national guidelines for management of COPD in Europe. European Respiratory Journal, 2016, 47, 625-637.	6.7	145
137	Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419.	6.7	746
138	Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention. Respiratory Medicine, 2016, 111, 1-7.	2.9	50
139	Effect of tiotropium on COPD exacerbations: A systematic review. Respiratory Medicine, 2016, 114, 1-8.	2.9	22
140	Wall stress determines systolic and diastolic function — Characteristics of heart failure. International Journal of Cardiology, 2016, 202, 685-693.	1.7	35
141	From Heart Failure to Highly Unsaturated Fatty Acid Deficiency and Vice Versa: Bidirectional Heart and Liver Interactions. Canadian Journal of Cardiology, 2016, 32, 217-225.	1.7	9
142	Late Gadolinium Enhancement in Sarcoidosis. Chest, 2015, 147, e118.	0.8	2
143	Excess Costs of Comorbidities in Chronic Obstructive Pulmonary Disease: A Systematic Review. PLoS ONE, 2015, 10, e0123292.	2.5	39
144	Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease. PLoS ONE, 2015, 10, e0132227.	2.5	55

#	Article	IF	CITATIONS
145	Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction. Respiratory Research, 2015, 16, 85.	3.6	23
146	Changes in GOLD: today and tomorrow. Lancet Respiratory Medicine, the, 2015, 3, 424-426.	10.7	4
147	Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. European Respiratory Journal, 2015, 45, 1273-1282.	6.7	22
148	One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 484-493.	1.6	29
149	Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure. Respiratory Medicine, 2015, 109, 1131-1137.	2.9	20
150	Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review. PLoS ONE, 2015, 10, e0132670.	2.5	40
151	COPD assessment: I, II, III, IV and/or A, B, C, D. European Respiratory Journal, 2014, 43, 949-950.	6.7	8
152	Gardening can induce pulmonary failure: Aspergillus ARDS in an immunocompetent patient, a case report. BMC Infectious Diseases, 2014, 14, 600.	2.9	4
153	Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respiratory Medicine,the, 2014, 2, 44-53.	10.7	44
154	Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naÃ <sup>-</sup> ve patients. Respiratory Medicine, 2013, 107, 75-83.	2.9	20
155	Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respiratory Research, 2013, 14, 116.	3.6	65
156	Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011, 364, 1093-1103.	27.0	603
157	Treating the Systemic Effects of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2011, 8, 376-379.	3.5	12
158	Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respiratory Research, 2010, 11, 79.	3.6	107